Bassil Dahiyat has been Xencor’s president and chief executive officer since the Company’s incorporation in August 1997. He is the co-founder of Xencor and co-inventor of Xencor’s breakthrough XmAb® technology. He has led the Company in creating a diverse clinical-stage portfolio of engineered antibodies and cytokines for the treatment of life-threatening and debilitating diseases, and has established alliances with leading biopharmaceutical companies that have resulted in three marketed drugs. Dr. Dahiyat has co-authored numerous scientific papers in the fields of protein design and drug delivery, is an inventor of over 30 U.S. and numerous foreign patents and has received scientific awards from the American Chemical Society, the Controlled Release Society, the Protein Society and Caltech. Dr. Dahiyat also serves as a member of the board of directors of Kodiak Sciences, a publicly traded biopharmaceutical company, and Terray Therapeutics, a private biotechnology company. He holds a Ph.D. in Chemistry from Caltech and B.S. and M.S.E. degrees in Biomedical Engineering from the Johns Hopkins University.

Dr. Desjarlais oversees all aspects of discovery and research at the company including technology development, protein and antibody engineering and generation of drug candidates and has served as chief scientific officer since 2014. Prior to joining Xencor in 2001, Dr. Desjarlais was an Assistant Professor of Chemistry at Penn State University, where he developed protein engineering methods. He then conducted postdoctoral research at the University of California, Berkeley. Dr. Desjarlais received a B.S. in physics from the University of Massachusetts and a Ph.D. in biophysics from Johns Hopkins University. He completed a post-doctoral fellowship at the University of California, Berkeley.

Ms. Eckert joined Xencor as vice president, general counsel and corporate secretary in September 2019. Previously she served as vice president, corporate legal at Synthetic Genomics, Inc. In that role she negotiated licensing and financial transactions and supported other corporate legal matters. Prior to Synthetic Genomics, Ms. Eckert served as associate general counsel at Sequenom and as senior director, legal affairs at Prometheus Laboratories. At Prometheus, she structured transactions, managed substantial patent litigation and supported the growth of the company’s commercial organization. Earlier in her career, she was an associate at Pillsbury Winthrop Shaw Pittman LLP and at Jones Day. Ms. Eckert earned a B.A. in political science from the University of California, Los Angeles, and a J.D. from the University of California, Hastings School of Law.

Dr. Grunstein brings more than 15 years of expertise in partnering, acquisitions and licensing in the biopharmaceutical industry and will lead strategic partnering to enhance the development of Xencor’s pipeline of drug candidates. Dr. Grunstein joins Xencor from Amgen, where he served in several strategic business development roles. Most recently, he served as executive director, transactions, where he led product and platform technology transactions and managed Amgen’s out-licensing and corporate equity portfolio. Prior to joining Amgen, Dr. Grunstein earned an MBA from the Sloan School of Management at the Massachusetts Institute of Technology and completed a post-doctoral fellowship in the Department of Molecular Oncology at Genentech. He earned a Ph.D. in biology from the University of California, San Diego, and a B.S. in biology from the University of California, Los Angeles.

Mr. Kuch has primary responsibility for financial reporting, budgeting, cash-flow management, investments, information technology and facilitiesfor the company. He has served as Xencor’s chief financial officer since 2018. He has extensive experience working with emerging companies through the IPO process. Prior to joining Xencor in 2000, he worked over 15 years in public accounting, most recently as a Director at Price Waterhouse. Mr. Kuch is a C.P.A. and received his B.S. and M.S. in accounting from the University of Illinois.

Mr. Rosemark brings to Xencor over 25 years of biopharmaceutical industry experience, leading regulatory affairs and quality assurance organizations, developing and registering products with regulatory authorities and supporting them throughout their lifecycles. Prior to joining Xencor, he most recently served as vice president, regulatory affairs at Beigene (USA), where he developed and evaluated regulatory approval strategies for multiple development projects and combinations thereof and held responsibility for 14 INDs. Before Beigene, Mr. Rosemark was vice president, regulatory affairs and quality assurance at CymaBay Therapeutics, where he led the regulatory strategies for several mid-to-late stage programs, several of which with preferential designations with health authorities. From 2003 to 2014, he was vice president, regulatory affairs and quality assurance at Exelixis, where he led to the regulatory team on the Cometriq^® program, taking it from discovery through approvals in the U.S. and EU. Earlier in his career he held roles of increasing responsibility in regulatory affairs at Solvay Pharmaceuticals, Ciba Vision and Bausch & Lomb Pharmaceuticals. Mr. Rosemark received a B.S. in chemistry from Cleveland State University.

Dr. Yang is responsible for leading clinical development strategy and overseeing clinical operations for Xencor’s portfolio of XmAb® drug candidates. Prior to joining Xencor in 2019, he served as senior vice president, head of clinical development and acting chief medical officer at Jazz Pharmaceuticals. Before assuming this role at Jazz, Dr. Yang was the therapeutic area head for hematology and oncology, assembling its clinical development team and overseeing several oncology products, including Erwinaze®, Defitelio® and Vyxeos®. Prior to Jazz, Dr. Yang led clinical development and clinical operations groups at Spectrum Pharmaceuticals, where he was vice president of clinical research. Previously, he held several roles of increasing responsibility at Amgen, including those of global development leader for Aranesp® in oncology and clinical research medical director for Blincyto®, the first bispecific antibody approved by the FDA. Before transitioning to the biopharmaceutical industry, Dr. Yang practiced medicine for several years as an academic oncologist at the University of Southern California, where he led a translational cancer research laboratory. Dr. Yang earned a B.A. in molecular biology from the University of California, Berkeley, and a Ph.D. in biochemistry and an M.D. from the University of Southern California. He completed his medical oncology fellowship at the MD Anderson Cancer Center.

Mr. Kowack oversees all aspects of the program leadership and strategic alliances group in support of Xencor’s internal and external portfolios. Previously, he served as vice president of program leadership and precision medicine at Ignyta, where he led early-stage development programs and spearheaded Ignyta’s contributions to the Cancer Moonshot initiative. Eric has extensive experience building and leading oncology-focused drug development teams, where at Pfizer he served as executive director and oncology asset team leader for 19 different programs, including Ibrance^® (palbociclib) from Ph 1b to approval. Before entering the biopharmaceutical industry, Eric served on active duty in the United States Coast Guard in several roles of increasing responsibility and then continued to serve in a reserve capacity across the U.S. Eric received an M.S. in biochemistry from Dartmouth College and an MBA from Marist College and is Commander, USCGR (retired).

Ms. Sandoz brings 25 years of wide-ranging healthcare experience to Xencor, where she is responsible for leading Xencor’s overall human resources strategy. Prior to joining Xencor, Ms. Sandoz served as Vice President, Human Resources at Surgical Care Affiliates, an OptumCare company, where she led teams in talent acquisition, compensation, and learning & organizational development. Before Surgical Care Affiliates, she held progressively more senior roles in human resources at Amgen, following a role as a program manager on their first oncology BLA submission, for Vectibix® (panitumumab). Earlier in her career, she worked in management consulting at Deloitte and in clinical research at Parke-Davis (now Pfizer). Ms. Sandoz received a B.S. in nursing from the University of Pennsylvania and an M.S. in nursing from the University of Michigan.